Results of the multi-center, randomized, comparator-controlled phase III NETTER-2 trial show that first-line treatment with radioligand therapy 177LU-DOTATATE in combination…
featured news
The Vall d’Hebron University Hospital Accredited Health Institute (ISS-IR-HUVH) has been one of those selected for the Fortalece -Salud program…
The biotech company Peptomyc SL and the Vall d’Hebron Institute of Oncology announced today that the public-private collaborators have been…
Led by investigators of the Vall d’Hebron Institute of Oncology’s (VHIO) Experimental Hematology Group and the Advanced Therapies Program of…
Published in the journal ESMO Gastrointestinal Oncology, results of a VHIO-led retrospective and multicenter study show that 3.4% of pancreatic…
Published as a Resource article in the open access journal Cell Reports*, results from an international study co-led by investigators…
Published in The Lancet, results of the randomized phase III BEATcc academic trial (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030) show that adding immune checkpoint…
VHIO consolidates its advanced therapy programme to develop new innovative treatments against cancer
The 1st VHIO-BBVA Foundation International Symposium on Cell-based Therapies in Oncology , organised by Dr. Alena Gros, head of the…
Vall d’Hebron Barcelona Hospital Campus has celebrated its first PhD Day, a whole day of scientific activities created for and…
Biliary tract cancer (BTC) poses a distinctive challenge in oncology, mainly due to diagnosis at late-stage and limited effective systemic…